December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

265.15 USD UNCHANGED
Streaming Delayed Price Updated: 6:31 AM EST, Jan 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2
...
51 52 53 54 55 56 57 58 Next >
Biogen Idec to Present at the Thomas Weisel Partners Healthcare Conference
From Business Wire News Releases
Seven Summits Research Releases Comments on CVX, MRVL, MS, BIIB, and CTX
From PR Newswire
Revised version: Veritude Announces Partnership with Biogen Idec for Managed Services Program
From PR Newswire
Biogen Idec Selects Veritude's Managed Services Program
-- Global Leader in Biotechnology Turns to Veritude to Support Temporary Staffing Requirements -- 
From PR Newswire
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
From Business Wire News Releases
Phase II Clinical Trial Results for ADENTRI Published in Journal of the American College of Cardiology
From Business Wire News Releases
Monday's Stock to Watch: BQTG! August 13, 2007
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Stock Market Alerts. 
From Marketwired News Releases
Biogen Idec Names Paul J. Clancy Chief Financial Officer
From Business Wire News Releases
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
From Business Wire News Releases
Investment News Alerts Hot Stock Pick's for Thursday, July 26th, 2007!
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO Circuit. 
From Marketwired News Releases
Seven Summits Research Releases Alerts on AXP, MCD, NYX, BIIB, and STM
From PR Newswire
Biogen Idec Reports Second Quarter 2007 Results
From Business Wire News Releases
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
As of Mid-July, Approximately 14,000 Patients on Therapy Worldwide 
From Business Wire News Releases
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
From Business Wire News Releases
Biogen Idec To Report Second Quarter 2007 Financial Results on July 24, 2007
From Business Wire News Releases
Seven Summits Research Releases Comments on VLO, AIG, MAR, GG, and BIIB
From PR Newswire
TYSABRI(R) Recommended by NICE for Use in Highly Active Relapsing Remitting Multiple Sclerosis in the Final Appraisal Determination
New Hope For People With Highly Active Multiple Sclerosis 
From Business Wire News Releases
Biogen Idec Announces Final Results of Its Modified ''Dutch Auction'' Tender Offer
From Business Wire News Releases
Biogen Idec and Cardiokine Partner to Develop Lixivaptan, a Novel Vasopressin Antagonist
Lixivaptan to enter Phase III clinical trial in 2007 in heart failure patients 
From Business Wire News Releases
Biogen Idec Announces Management Change
From Business Wire News Releases
Biogen Idec Announces Preliminary Results of Its Modified ''Dutch Auction'' Tender Offer
From Business Wire News Releases
Wall Street News Alert Issues Special Alert on BQTG! June 26, 2007
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding. 
From Marketwired News Releases
UCB and Biogen Idec's oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
From Marketwired News Releases
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
From Business Wire News Releases
Biogen Idec to Present at the Jefferies Healthcare Conference
From Business Wire News Releases
Biogen Idec to Present at the 17th Annual Wachovia Nantucket Equity Conference
From Business Wire News Releases
Zacks Bull and Bear of the Day Highlights: Crocs, Amylin Pharmaceuticals, Texas Instruments and Biogen Idec
From Business Wire News Releases
Biogen Idec to Present at the Goldman Sachs 28th Annual Global Healthcare Conference
From Business Wire News Releases
Biogen Idec Elects Thermo Fisher Scientific CEO to Board of Directors
From Business Wire News Releases
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Data Presented at ASCO Show Increase in Complete Responses 
From Business Wire News Releases
< Previous 1 2
...
51 52 53 54 55 56 57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.